Skip to content

Eli Lilly Adds Support for Drug Transparency Laws

080528_lilly1.jpgAmid increasing governmental and professional concerns about payments to physicians by pharmaceutical companies, major drug manufacturer Eli Lilly announced its support for legislation to increase public trust in the healthcare industry. Independent studies have shown a significant financial link between the drug industry and practicing physicians. Ninety-four percent of doctors reported that they have some type of beneficial relationship with the drug industry. A recent editorial in the Journal of the American Medical Association suggesting that physicians should be required to disclose financial ties with the pharmaceutical industry led to swift Senate action calling for a federally-legislated financial disclosure law also known as the “Sunshine Act.” The bipartisan bill (S. 2029) would establish a national registry of payments to physicians by companies selling medical devices, medical supplies and pharmaceuticals. In response to the federal action, leading drug maker Eli Lilly and Company came out in support of the bill. “Lilly welcomes greater transparency in the healthcare system and believes this legislation represents an important step in building public trust and confidence in the relationships between the pharmaceutical and device industries and physicians,” said John C. Lechleiter, Ph.D., president and chief executive officer of Eli Lilly and Company. Support for the Sunshine Act is the newest addition to what Lilly terms its “transparency agenda.” In 2004, Lilly became the first company to voluntarily make public its clinical trials and clinical trials data. That information can be found at www.lillytrials.com. Image source: a.abcnews.com. > Continue.

News selected by Covalence | Country: USA | Company: Eli Lilly | Source: Spectrum online

Back To Top